Company profile: Antigen Express
1.1 - Company Overview
Company description
- Provider of proprietary vaccine formulation platform and products addressing large unmet medical needs by focusing on stimulation of critical T helper cells. The technology enables antigen-specific stimulation or suppression of T-helper responses to virtually any antigen.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Antigen Express
CatalYm
HQ: Germany
Website
- Description: Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CatalYm company profile →
Immunomedics
HQ: United States
Website
- Description: Provider of monoclonal antibody-based products for the treatment of cancer and other serious diseases, specializing in their development as part of a corporate objective to become a fully-integrated biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunomedics company profile →
Barinthus Bio
HQ: United Kingdom
Website
- Description: Provider of clinical-stage immunotherapeutics and vaccines for infectious diseases and cancer, leveraging proprietary ChAdOx1/ChAdOx2 adenoviral vectors and MVA platforms to prime disease-specific T cells. Pipeline includes VTP-300 for chronic Hepatitis B, VTP-850 for prostate cancer, VTP-1000 for celiac disease, and the SNAP-TI platform to promote immune tolerance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Barinthus Bio company profile →
Proteomedix
HQ: Switzerland
Website
- Description: Provider of blood-based prostate cancer diagnostics, notably Proclarix: a test panel that integrates biomarkers and patient data to compute a risk score for high-grade prostate cancer using samples taken for PSA testing. Clinical evidence from 955 subjects shows Proclarix reduces unnecessary biopsies by accurately detecting clinically significant cancer; offers biomarker signatures for diagnosis, prognosis, and therapy management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proteomedix company profile →
Kinnate Biopharma
HQ: United States
Website
- Description: Provider of precision oncology therapeutics for genomically-defined cancers, leveraging structure-based drug discovery and translational research. Pipeline includes exarafenib (KIN-2787), a pan-RAF inhibitor for BRAF/NRAS-driven tumors; KIN-3248 targeting FGFR2/3 alterations in intrahepatic cholangiocarcinoma and urothelial carcinoma; KIN-8741, a selective c-MET inhibitor; and a potentially brain-penetrant CDK4 inhibitor for adult solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinnate Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Antigen Express
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Antigen Express
2.2 - Growth funds investing in similar companies to Antigen Express
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Antigen Express
4.2 - Public trading comparable groups for Antigen Express
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →